^
Association details:
Biomarker:EML4-ALK variant 3
Cancer:Lung Adenocarcinoma
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Source:
Title:

Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor.

Published date:
05/19/2021
Excerpt:
A 54-year-old never-smoker man who had been diagnosed with lung adenocarcinoma stage IVa (T3N1M1a). He received standard first-line therapy with platinum-based chemotherapy, immunotherapy and antiangiogenics achieving tumor progression. A next-generation sequencing (NGS) panel revealed the presence of the EML4-ALK fusion variant 3a/b.
DOI:
10.1200/JCO.2021.39.15_suppl.e21014